CN112206200A - Full-effect crystal eye mask and preparation method thereof - Google Patents
Full-effect crystal eye mask and preparation method thereof Download PDFInfo
- Publication number
- CN112206200A CN112206200A CN202010989222.6A CN202010989222A CN112206200A CN 112206200 A CN112206200 A CN 112206200A CN 202010989222 A CN202010989222 A CN 202010989222A CN 112206200 A CN112206200 A CN 112206200A
- Authority
- CN
- China
- Prior art keywords
- additive
- mixture
- water
- effect
- efficacy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 230000000694 effects Effects 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 235000011187 glycerol Nutrition 0.000 claims abstract description 21
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- -1 polydimethylsiloxane Polymers 0.000 claims abstract description 11
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000003750 conditioning effect Effects 0.000 claims abstract description 10
- 229920000161 Locust bean gum Polymers 0.000 claims abstract description 9
- 235000010420 locust bean gum Nutrition 0.000 claims abstract description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 8
- 239000000679 carrageenan Substances 0.000 claims abstract description 8
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 8
- 229920001525 carrageenan Polymers 0.000 claims abstract description 8
- 229940113118 carrageenan Drugs 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 8
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 8
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims abstract description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 6
- 229940073490 sodium glutamate Drugs 0.000 claims abstract description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 5
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004698 Polyethylene Substances 0.000 claims abstract description 5
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims abstract description 5
- 229960000458 allantoin Drugs 0.000 claims abstract description 5
- 229940081733 cetearyl alcohol Drugs 0.000 claims abstract description 5
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 5
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940075529 glyceryl stearate Drugs 0.000 claims abstract description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 5
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000711 locust bean gum Substances 0.000 claims abstract description 5
- 229940041616 menthol Drugs 0.000 claims abstract description 5
- 229940089508 methyl diisopropyl propionamide Drugs 0.000 claims abstract description 5
- 239000002480 mineral oil Substances 0.000 claims abstract description 5
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 5
- CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 5
- 229920000573 polyethylene Polymers 0.000 claims abstract description 5
- 239000001508 potassium citrate Substances 0.000 claims abstract description 5
- 229960002635 potassium citrate Drugs 0.000 claims abstract description 5
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims abstract description 5
- 235000011082 potassium citrates Nutrition 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims description 63
- 230000000996 additive effect Effects 0.000 claims description 63
- 239000000047 product Substances 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 16
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 6
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 6
- 102000016942 Elastin Human genes 0.000 claims description 6
- 108010014258 Elastin Proteins 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 229920002549 elastin Polymers 0.000 claims description 6
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 6
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 5
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 5
- 229940108325 retinyl palmitate Drugs 0.000 claims description 5
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 5
- 239000011769 retinyl palmitate Substances 0.000 claims description 5
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 4
- FDHNLHLOJLLXDH-JIYHLSBYSA-N (e)-3-(3-hydroxy-4-methoxyphenyl)-1-[2-hydroxy-6-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]prop-2-en-1-one Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C(=O)C(C(=C1)OC)=C(O)C=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 FDHNLHLOJLLXDH-JIYHLSBYSA-N 0.000 claims description 4
- YDSVPIYLRFZLAT-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N Chemical compound C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N YDSVPIYLRFZLAT-UHFFFAOYSA-N 0.000 claims description 4
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims description 4
- 108010016626 Dipeptides Proteins 0.000 claims description 4
- 241000237858 Gastropoda Species 0.000 claims description 4
- 244000181025 Rosa gallica Species 0.000 claims description 4
- LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 claims description 4
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 4
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229940076640 hesperidin methylchalcone Drugs 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 235000015424 sodium Nutrition 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 claims description 3
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 240000002234 Allium sativum Species 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 241001506047 Tremella Species 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 3
- 235000004611 garlic Nutrition 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 229940051250 hexylene glycol Drugs 0.000 claims description 3
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 229940100459 steareth-20 Drugs 0.000 claims description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- YVBGRQLITPHVOP-UHFFFAOYSA-L disodium;[hydroxy-[hydroxy(oxido)phosphoryl]oxyphosphoryl] hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)(=O)OP(O)([O-])=O YVBGRQLITPHVOP-UHFFFAOYSA-L 0.000 claims description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 2
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 claims description 2
- 244000170916 Paeonia officinalis Species 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000007794 irritation Effects 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 40
- 208000026935 allergic disease Diseases 0.000 description 40
- 230000007815 allergy Effects 0.000 description 40
- 210000003491 skin Anatomy 0.000 description 37
- 230000014759 maintenance of location Effects 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 235000002673 Dioscorea communis Nutrition 0.000 description 6
- 241000544230 Dioscorea communis Species 0.000 description 6
- 208000035753 Periorbital contusion Diseases 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000013538 functional additive Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 244000075850 Avena orientalis Species 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 3
- 244000178870 Lavandula angustifolia Species 0.000 description 3
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 150000002333 glycines Chemical class 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 240000009108 Chlorella vulgaris Species 0.000 description 2
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 235000007558 Avena sp Nutrition 0.000 description 1
- 235000013913 Ceratonia Nutrition 0.000 description 1
- 241001060815 Ceratonia Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- 241000908178 Tremella fuciformis Species 0.000 description 1
- 241000062949 Tremula Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229940033631 carrageenan sodium Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940043431 ceratonia Drugs 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000020721 horse chestnut extract Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a full-effect crystal eye mask which comprises the following components in percentage by weight: 1-10% of glycerin, 0.1-2% of locust bean gum, 0.1-2% of sodium carrageenan, 0.1-2% of p-hydroxyacetophenone, 0.1-2% of caprylyl hydroximic acid, 0.01-1% of citric acid, 0.1-5% of potassium citrate, 0.01-1% of PEG-12 polydimethylsiloxane, 0.01-1% of allantoin, 0.01-1% of poly gamma-sodium glutamate, 0.001-1% of sodium hyaluronate, 0.01-0.1% of first skin conditioner, 0.01-1% of second skin conditioner and the balance of water; the first skin conditioning agent is a mixture of menthol lactate, methyl diisopropyl propionamide and menthane formylethylamine; the second skin conditioning agent is a mixture of isopropyl palmitate, cetearyl alcohol, mineral oil, polyethylene glycol-20, sucrose stearate, glyceryl stearate, 1, 2-hexanediol, and tocopheryl acetate. The full-effect crystal eye mask can be used for a long time at a time, and the using time of the full-effect crystal eye mask is 3 times that of a common eye mask; and various effects are used, so that the use amount of the effects is reduced while the effects are maintained, and the irritation of the effects on eyes is reduced.
Description
Technical Field
The invention relates to the technical field of eye care, in particular to a full-effect crystal eye mask and a preparation method thereof.
Background
It is well known that the periocular skin physiological characteristics are different from facial skin. One is that the skin is thin, the thickness of the skin is only about 2/3 of normal skin, and the skin is tender and fragile; secondly, the skin has less elastic fiber and is easy to loose; the third is that the blood circulation is rich, the capillary vessel is thin, and blood stasis and edema are easy to happen. In addition, the movement of facial expression muscles pulls the skin around the eyes, making it prone to wrinkles and aging. Thus, the skin around the eyes requires special moisturizing care.
Eyes are the window of soul, and people are constantly pursuing to maintain the good state of eye skin. However, with age, collagen fibers and elastic fibers of the skin are continuously lost, the water-retaining ability is lowered, and wrinkles gradually occur. And modern people can also have eye problems such as dark eye circles, eye bags and the like due to irregular diet and work and rest and the like.
At present, a plurality of skin care products for eye skin exist, and a common skin care product is possibly not suitable for the skin around eyes or cannot play a corresponding nursing role, cannot aim at physiological characteristics of thinner, sensitive and difficult moisture retention of the eye skin and the like, or has a poor eye nursing effect. In order to achieve obvious effects in eye care products on the market, the concentration of the added efficacy substances in the eye care products is higher. For eye marks, nicotinamide (5-10%), vitamin A derivatives (1-5%), polypeptide (5-20%) and other raw materials are generally adopted; for dark circles, rehmannia root extract (1-5%) and other raw materials are generally adopted; for pouch, caffeine (1-3%), horse chestnut extract (1-5%) and other raw materials are generally used. However, high concentrations of the benefit agent tend to cause irritation and sensitization of the skin, thereby producing an effect that is contrary to what is intended.
In addition to the problems presented above, the addition of a single agent results in a relatively single effect. There are many reasons for black eye, wrinkles, etc. on eyes, so we need to screen and find out suitable active substances by studying the root cause of eye problems, analyze the action mechanism, and achieve the purpose of 'medicine preparation for symptoms', thus solving the problems fundamentally.
Disclosure of Invention
In order to solve the defects of the prior art, the invention provides a full-effect crystal eye mask and a preparation method thereof.
The technical scheme adopted by the invention is as follows:
a full-effect crystal eye mask comprises the following components in percentage by weight: 1-10% of glycerin, 0.1-2% of locust bean gum (CERATONIA SILIQIA), 0.1-2% of carrageenan sodium, 0.1-2% of p-hydroxyacetophenone, 0.1-2% of caprylyl hydroximic acid, 0.01-1% of citric acid, 0.1-5% of potassium citrate, 0.01-1% of PEG-12 polydimethylsiloxane, 0.01-1% of allantoin, 0.01-1% of poly-gamma-sodium glutamate, 0.001-1% of sodium hyaluronate, 0.01-0.1% of first skin conditioner, 0.01-1% of second skin conditioner and the balance of water; the first skin conditioning agent is a mixture of menthol lactate, methyl diisopropyl propionamide and menthane formylethylamine; the second skin conditioning agent is a mixture of isopropyl palmitate, cetearyl alcohol, mineral oil, polyethylene glycol-20, sucrose stearate, glyceryl stearate, 1, 2-hexanediol, and tocopheryl acetate.
Further, the paint also comprises the following components in percentage by weight: 0.01-1% of nicotinamide, 0.01-1% of ROSA DAMASCENA (ROSA DAMASCENA) flower water, 0.01-5% of hydrolyzed collagen, 0.01-2% of TREMELLA FUCIFORMIS (tremula FUCIFORMIS) fruiting body extract, 0.01-1% of lavender (LAVANDULA ANGUSTIFOLIA) oil, 0.01-10% of effect additive A, 0.01-10% of effect additive B, 0.01-5% of effect additive C, 0.01-5% of effect additive D, 0.01-3% of effect additive E, 0.01-5% of effect additive F, 0.01-2% of effect additive G, 0.01-10% of effect additive H, 0.01-5% of effect additive I and 0.01-5% of effect additive J.
Specifically, the efficacy additive A is a mixture of water, glycerin, oat (AVENA SATIVA) peptide, hexylene glycol, 1, 3-propylene glycol, and caprylyl hydroxamic acid; the efficacy additive B is a mixture of snail secretion filtrate and butanediol; the functional additive C is a mixture of semen GLYCINEs (Glycine SOJA) extract, water and butanediol; the functional additive D is a mixture of water, butanediol, ethanol, Chlorella VULGARIS (Chlorella VULGARIS) extract, Paeonia SUFFRUTICOSA (Paeonia SUFFRUTICOSA) root extract, Bulbus Allii (Allium SATIVUM) bulb extract and disodium adenosine triphosphate; the efficacy additive E is a mixture of water, glycerol, hesperidin methyl chalcone, steareth-20, dipeptide-2, palmitoyl tetrapeptide-7 and chlorhexidine digluconate; the efficacy additive F is a mixture of hydrolyzed elastin, water and ethylhexyl glycerin; the efficacy additive G is a mixture of retinol palmitate and tocopherol (vitamin E); the efficacy additive H is a mixture of water, glycerol, butanediol, carbomer, polysorbate-20, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7; the efficacy additive I is a mixture of water and acetyl hexapeptide-8; the efficacy adding machine J is a mixture of water, glycerol and dipeptide diaminobutyrylbenzylamide diacetate.
Wherein, the function additive A has the functions of keeping moisture, softening fine lines, accelerating cell proliferation, promoting skin metabolism, activating skin, reducing skin roughness and resisting free radicals in the formula. The function of the efficacy additive B in the formula is antioxidation, anti-aging, moisture retention and skin regeneration. The function of the efficacy additive C in the formula is to stimulate collagen synthesis, promote anti-inflammatory activity and inhibit free radicals. The functional additive D has the functions of diminishing inflammation, whitening, promoting blood circulation, activating cells, preserving moisture, promoting lipolysis and resisting oxidation in the formula. The function of the efficacy additive E in the formula is to enhance microcirculation, tighten and smooth skin of capillary vessels; increasing the blood vessel expansion force and accelerating the blood circulation; enhancing the elasticity of the eyes. The function of the effect additive F in the formula is moisture retention and elastin supplement. The function of the efficacy additive G in the formula is to stimulate the generation of collagen and increase the synthesis of elastin; stimulating the regeneration of skin cells and repairing the skin after being sunned; increase epidermal proliferation and thickness, enhance keratinocyte desquamation, reduce melanin content, and reduce color spots. The function of the efficacy additive H in the formula is anti-aging, wrinkle removing, collagen and polysaccharide synthesis promoting, and collagen after UVA damage repairing. The function of the efficacy additive I in the formula is to compete for SNAP-25 at the site of the fused vesicle complex, influence the formation of the complex and enable the vesicle not to effectively release neurotransmitters. The function of the functional additive J in the formula is to relax muscles, tighten and resist wrinkles and recover elasticity.
The invention also comprises a preparation method of the full-effect crystal eye mask, which comprises the following steps:
s1, adding water, glycerol, carob bean gum, sodium carrageenan and p-hydroxyacetophenone into a water phase pot according to the weight percentage, heating to 85-90 ℃, stirring and dissolving until the mixture is completely transparent to obtain a first reaction solution;
s2, cooling the first reaction solution to 70-75 ℃, adding other components according to the weight percentage, and uniformly stirring for 5-10 minutes to obtain a second reaction solution;
and S3, pouring the second reaction solution into a mold for molding, cooling (air cooling) to normal temperature, and packaging to obtain a finished product.
The invention uses sodium hyaluronate, tocopherol, poly gamma-sodium glutamate, tremella extract, chlorella extract, snail secretion filtrate and oat peptide to supplement and maintain the moisture of the cuticle; acetyl hexapeptide-8, dipeptide diaminobutyrylbenzylamide diacetate relaxes muscle; retinol palmitate, extract of semen glycines, palmitoyl tripeptide-1 stimulate collagen production; hydrolyzing collagen and elastin to supplement collagen fiber and elastic fiber; extracts of Lavender, Nicotinamide, and peony root are antioxidant; whitening with retinol palmitate, nicotinamide, and Chlorella extract; the chlorella promotes lipolysis; bulbus Allii bulb extract, hesperidin methyl chalcone, dipeptide-2, and semen glycines seed extract can promote blood circulation.
Compared with the prior art, the invention has the advantages that:
1. the eye mask provided by the invention can continuously improve the safety of the formula while ensuring the efficacy of the eye mask, and can reduce the irritation to the eye skin on the premise of achieving the efficacy by adjusting the lowest effective concentration of the synergistic effect of various efficacy substances. The crystal film has the advantages that the crystal film is breathable and does not absorb reversely, the eye film can be pasted on the skin for a long time, the film body becomes thin slowly along with the increase of the pasting time, is more compact but not dry, can keep moist and nutrition, provides sufficient time for the skin to absorb active matters with lower concentration, and has no foreign body sensation.
2. The full-effect crystal eye mask prepared by the invention can be used for a long time at one time, and the using time can reach 3 times of that of a common eye mask. And multiple effect substances are compounded, so that the use amount of the effect substances is reduced while the effect is maintained, and the irritation of the effect substances to eyes is reduced.
Detailed Description
Example 1
A full-effect crystal eye mask comprises the following components in percentage by weight: 1-10% of glycerin, 0.1-2% of locust bean gum, 0.1-2% of sodium carrageenan, 0.1-2% of p-hydroxyacetophenone, 0.1-2% of caprylyl hydroximic acid, 0.01-1% of citric acid, 0.1-5% of potassium citrate, 0.01-1% of PEG-12 polydimethylsiloxane, 0.01-1% of allantoin, 0.01-1% of poly gamma-sodium glutamate, 0.001-1% of sodium hyaluronate, 0.01-0.1% of first skin conditioner, 0.01-1% of second skin conditioner and the balance of water; the first skin conditioning agent is a mixture of menthol lactate, methyl diisopropyl propionamide and menthane formylethylamine; the second skin conditioning agent is a mixture of isopropyl palmitate, cetearyl alcohol, mineral oil, polyethylene glycol-20, sucrose stearate, glyceryl stearate, 1, 2-hexanediol, and tocopheryl acetate.
The preparation method of the full-effect crystal eye mask comprises the following steps:
s1, adding water, glycerol, carob bean gum, sodium carrageenan and p-hydroxyacetophenone into a water phase pot according to the weight percentage, heating to 85-90 ℃, stirring and dissolving until the mixture is completely transparent to obtain a first reaction solution;
s2, cooling the first reaction solution to 70-75 ℃, adding other components according to the weight percentage, and uniformly stirring for 5-10 minutes to obtain a second reaction solution;
and S3, pouring the second reaction solution into a mold for molding, cooling (air cooling) to normal temperature, and packaging to obtain a finished product.
For a better explanation and illustration of the present example, the following five groups (groups 1-5) of eye membrane composition ratios are specifically listed, and group 6 is set as a control:
the above six groups of formulations were evaluated:
(1) test products: the crystal eye films of examples 1 to 6.
(2) The test population: 100 women aged between 20 and 40 years old.
(3) And (3) trial period: for 30 days.
(4) Health condition: the skin of the subject is healthy, has no allergic history of the skin disease, and meets the voluntary selection standard of the subject. The test evaluation results are shown in tables 1 to 6:
table 1, summary of trial feedback for group 1 products prepared
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 72 | 11 | 15 | 2 | 0 | No allergy phenomenon |
| Skin-sticking sense | 92 | 2 | 6 | 0 | 0 | No allergy phenomenon |
| Safety feature | 90 | 8 | 2 | 0 | 0 | No allergy phenomenon |
TABLE 2 summary of trial feedback for products prepared in group 2
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 78 | 11 | 11 | 0 | 0 | No allergy phenomenon |
| Skin-sticking sense | 92 | 4 | 4 | 0 | 0 | No allergy phenomenon |
| Safety feature | 87 | 9 | 4 | 0 | 0 | No allergy phenomenon |
Table 3, summary of trial feedback for group 3 products prepared
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 78 | 11 | 11 | 0 | 0 | No allergy phenomenon |
| Skin-sticking sense | 90 | 7 | 3 | 0 | 0 | No allergy phenomenon |
| Safety feature | 70 | 17 | 12 | 1 | 0 | No allergy phenomenon |
TABLE 4 summary of trial feedback for group 4 products prepared
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 87 | 13 | 0 | 0 | 0 | No allergy phenomenon |
| Skin-sticking sense | 87 | 4 | 5 | 4 | 0 | No allergy phenomenon |
| Safety feature | 73 | 15 | 9 | 3 | 0 | No allergy phenomenon |
TABLE 5 trial feedback summary of products prepared in group 5
TABLE 6 summary of trial feedback for products prepared in group 6
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 82 | 15 | 3 | 0 | 0 | No allergy phenomenon |
| Skin-sticking sense | 84 | 12 | 4 | 0 | 0 | No allergy phenomenon |
| Safety feature | 72 | 22 | 6 | 0 | 0 | No allergy phenomenon |
The testers all show that the groups 1-5 have good effects on moisture retention, skin-sticking feeling and the like. Wherein, the product of group 2 is superior to the products of groups 1, 3-5, and the testers all approve the product of group 2.
Example 2
A full-effect crystal eye mask comprises the following components in percentage by weight: 1-10% of glycerin, 0.1-2% of locust bean gum, 0.1-2% of sodium carrageenan, 0.1-2% of p-hydroxyacetophenone, 0.1-2% of caprylyl hydroximic acid, 0.01-1% of citric acid, 0.1-5% of potassium citrate, 0.01-1% of PEG-12 polydimethylsiloxane, 0.01-1% of allantoin, 0.01-1% of poly gamma-sodium glutamate, 0.001-1% of sodium hyaluronate, 0.01-0.1% of first skin conditioner, 0.01-1% of second skin conditioner and the balance of water; the first skin conditioning agent is a mixture of menthol lactate, methyl diisopropyl propionamide and menthane formylethylamine; the second skin conditioning agent is a mixture of isopropyl palmitate, cetearyl alcohol, mineral oil, polyethylene glycol-20, sucrose stearate, glyceryl stearate, 1, 2-hexanediol, and tocopheryl acetate.
The full-effect crystal eye mask further comprises the following components in percentage by weight: 0.01-1% of nicotinamide, 0.01-1% of rosa damascena flower water, 0.01-5% of hydrolyzed collagen, 0.01-2% of tremella sporophore extract, 0.01-1% of lavender oil, 0.01-10% of effect additive A, 0.01-10% of effect additive B, 0.01-5% of effect additive C, 0.01-5% of effect additive D, 0.01-3% of effect additive E, 0.01-5% of effect additive F, 0.01-2% of effect additive G, 0.01-10% of effect additive H, 0.01-5% of effect additive I and 0.01-5% of effect additive J.
Specifically, the efficacy additive A is a mixture of water, glycerol, avenin, hexylene glycol, 1, 3-propylene glycol and caprylyl hydroximic acid; the efficacy additive B is a mixture of snail secretion filtrate and butanediol; the efficacy additive C is a mixture of a wild soybean seed extract, water and butanediol; the efficacy additive D is a mixture of water, butanediol, ethanol, chlorella extract, peony root extract, garlic bulb extract and adenosine disodium triphosphate; the efficacy additive E is a mixture of water, glycerol, hesperidin methyl chalcone, steareth-20, dipeptide-2, palmitoyl tetrapeptide-7 and chlorhexidine digluconate; the efficacy additive F is a mixture of hydrolyzed elastin, water and ethylhexyl glycerin; the efficacy additive G is a mixture of retinol palmitate and tocopherol; the efficacy additive H is a mixture of water, glycerol, butanediol, carbomer, polysorbate-20, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7; the efficacy additive I is a mixture of water and acetyl hexapeptide-8; the efficacy adding machine J is a mixture of water, glycerol and dipeptide diaminobutyrylbenzylamide diacetate.
The preparation method of the full-effect crystal eye mask comprises the following steps:
s1, adding water, glycerol, carob bean gum, sodium carrageenan and p-hydroxyacetophenone into a water phase pot according to the weight percentage, heating to 85-90 ℃, stirring and dissolving until the mixture is completely transparent to obtain a first reaction solution;
s2, cooling the first reaction solution to 70-75 ℃, adding other components according to the weight percentage, and uniformly stirring for 5-10 minutes to obtain a second reaction solution;
and S3, pouring the second reaction solution into a mold for molding, cooling (air cooling) to normal temperature, and packaging to obtain a finished product.
For a better explanation and illustration of the present example, the following five groups (groups 7-11) of eye membrane composition ratios are specifically listed, and group 12 is set as a control:
the above six groups of formulations were evaluated:
(1) test products: the crystal eye films of examples 1 to 6.
(2) The test population: 100 women aged between 20 and 40 years old.
(3) And (3) trial period: for 30 days.
(4) Health condition: the skin of the subject is healthy, has no allergic history of the skin disease, and meets the voluntary selection standard of the subject. The test evaluation results are shown in tables 7 to 12:
TABLE 7 summary of trial feedback for group 7 products prepared
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 85 | 11 | 4 | 0 | 0 | No allergy phenomenon |
| Eyeline removing device | 80 | 16 | 4 | 0 | 0 | No allergy phenomenon |
| Pouch removal | 80 | 12 | 8 | 0 | 0 | No allergy phenomenon |
| Black eye removing ring | 90 | 5 | 5 | 0 | 0 | No allergy phenomenon |
| Safety feature | 87 | 7 | 6 | 0 | 0 | No allergy phenomenon |
TABLE 8 summary of trial feedback for group 8 products prepared
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 95 | 4 | 1 | 0 | 0 | No allergy phenomenon |
| Eyeline removing device | 96 | 2 | 2 | 0 | 0 | No allergy phenomenon |
| Pouch removal | 90 | 4 | 1 | 0 | 0 | No allergy phenomenon |
| Black eye removing ring | 97 | 3 | 0 | 0 | 0 | No allergy phenomenon |
| Safety feature | 90 | 2 | 3 | 0 | 0 | No allergy phenomenon |
TABLE 9 summary of trial feedback for group 9 products prepared
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 83 | 10 | 7 | 0 | 0 | No allergy phenomenon |
| Eyeline removing device | 89 | 7 | 4 | 0 | 0 | No allergy phenomenon |
| Pouch removal | 81 | 11 | 8 | 0 | 0 | No allergy phenomenon |
| Black eye removing ring | 90 | 8 | 2 | 0 | 0 | No allergy phenomenon |
| Safety feature | 85 | 8 | 7 | 0 | 0 | No allergy phenomenon |
TABLE 10 summary of trial feedback for group 10 products prepared
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 78 | 16 | 6 | 0 | 0 | No allergy phenomenon |
| Eyeline removing device | 82 | 15 | 3 | 0 | 0 | No allergy phenomenon |
| Pouch removal | 80 | 10 | 10 | 0 | 0 | No allergy phenomenon |
| Black eye removing ring | 85 | 14 | 1 | 0 | 0 | No allergy phenomenon |
| Safety feature | 79 | 15 | 6 | 0 | 0 | No allergy phenomenon |
TABLE 11 summary of trial feedback for group 11 products prepared
| Evaluation item | Is very good | Good taste | In general | Is poor | Is very poor | Others |
| Moisture retention and moistening property | 85 | 11 | 4 | 0 | 0 | No allergy phenomenon |
| Eyeline removing device | 72 | 19 | 9 | 0 | 0 | No allergy phenomenon |
| Pouch removal | 75 | 12 | 13 | 0 | 0 | No allergy phenomenon |
| Black eye removing ring | 80 | 17 | 3 | 0 | 0 | No allergy phenomenon |
| Safety feature | 80 | 20 | 0 | 0 | 0 | No allergy phenomenon |
TABLE 12 summary of trial feedback for group 12 products prepared
The testers all show that the groups 1-5 have good effects on the aspects of moisturizing, wrinkle removing, pouch removing, dark eye ring removing, safety and the like. Wherein, the product of group 2 is superior to the products of groups 1, 3-5, and testers are especially approved for preparing the product of group 2.
The present invention is not limited to the above-described embodiments, and various modifications and variations of the present invention are intended to be included within the scope of the claims and the equivalent technology of the present invention if they do not depart from the spirit and scope of the present invention.
Claims (4)
1. The full-effect crystal eye mask is characterized by comprising the following components in percentage by weight: 1-10% of glycerin, 0.1-2% of locust bean gum, 0.1-2% of sodium carrageenan, 0.1-2% of p-hydroxyacetophenone, 0.1-2% of caprylyl hydroximic acid, 0.01-1% of citric acid, 0.1-5% of potassium citrate, 0.01-1% of PEG-12 polydimethylsiloxane, 0.01-1% of allantoin, 0.01-1% of poly gamma-sodium glutamate, 0.001-1% of sodium hyaluronate, 0.01-0.1% of first skin conditioner, 0.01-1% of second skin conditioner and the balance of water; the first skin conditioning agent is a mixture of menthol lactate, methyl diisopropyl propionamide and menthane formylethylamine; the second skin conditioning agent is a mixture of isopropyl palmitate, cetearyl alcohol, mineral oil, polyethylene glycol-20, sucrose stearate, glyceryl stearate, 1, 2-hexanediol, and tocopheryl acetate.
2. The full effect crystal eye mask according to claim 1, further comprising the following components in percentage by weight: 0.01-1% of nicotinamide, 0.01-1% of rosa damascena flower water, 0.01-5% of hydrolyzed collagen, 0.01-2% of tremella sporophore extract, 0.01-1% of lavender oil, 0.01-10% of effect additive A, 0.01-10% of effect additive B, 0.01-5% of effect additive C, 0.01-5% of effect additive D, 0.01-3% of effect additive E, 0.01-5% of effect additive F, 0.01-2% of effect additive G, 0.01-10% of effect additive H, 0.01-5% of effect additive I and 0.01-5% of effect additive J.
3. The full effect crystal eye mask as claimed in claim 2, wherein the effect additive A is a mixture of water, glycerin, avenin, hexylene glycol, 1, 3-propylene glycol and caprylyl hydroximic acid; the efficacy additive B is a mixture of snail secretion filtrate and butanediol; the efficacy additive C is a mixture of a wild soybean seed extract, water and butanediol; the efficacy additive D is a mixture of water, butanediol, ethanol, chlorella extract, peony root extract, garlic bulb extract and adenosine disodium triphosphate; the efficacy additive E is a mixture of water, glycerol, hesperidin methyl chalcone, steareth-20, dipeptide-2, palmitoyl tetrapeptide-7 and chlorhexidine digluconate; the efficacy additive F is a mixture of hydrolyzed elastin, water and ethylhexyl glycerin; the efficacy additive G is a mixture of retinol palmitate and tocopherol; the efficacy additive H is a mixture of water, glycerol, butanediol, carbomer, polysorbate-20, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7; the efficacy additive I is a mixture of water and acetyl hexapeptide-8; the efficacy adding machine J is a mixture of water, glycerol and dipeptide diaminobutyrylbenzylamide diacetate.
4. The method for preparing the full-effect crystal eye mask as claimed in any one of claims 1 to 3, which comprises the following steps:
s1, adding water, glycerol, carob bean gum, sodium carrageenan and p-hydroxyacetophenone into a water phase pot according to the weight percentage, heating to 85-90 ℃, stirring and dissolving until the mixture is completely transparent to obtain a first reaction solution;
s2, cooling the first reaction solution to 70-75 ℃, adding other components according to the weight percentage, and uniformly stirring for 5-10 minutes to obtain a second reaction solution;
and S3, pouring the second reaction solution into a mold for molding, cooling (air cooling) to normal temperature, and packaging to obtain a finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010989222.6A CN112206200A (en) | 2020-09-18 | 2020-09-18 | Full-effect crystal eye mask and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010989222.6A CN112206200A (en) | 2020-09-18 | 2020-09-18 | Full-effect crystal eye mask and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112206200A true CN112206200A (en) | 2021-01-12 |
Family
ID=74050137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010989222.6A Pending CN112206200A (en) | 2020-09-18 | 2020-09-18 | Full-effect crystal eye mask and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112206200A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112603871A (en) * | 2021-02-05 | 2021-04-06 | 东晟源研究院(广州)有限公司 | Formula and preparation method of wrinkle-reducing eye essence |
| CN113786376A (en) * | 2021-09-26 | 2021-12-14 | 湖北省麦诗特生物科技有限公司 | Eye cream composition with eyeprint removing effect and preparation method thereof |
| CN113876656A (en) * | 2021-10-29 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | Black eye and pouch removing soluble beautifying microneedle patch composition and preparation method thereof |
| CN115006322A (en) * | 2022-06-06 | 2022-09-06 | 广东丸美生物技术股份有限公司 | Formula of instant and long-acting multifunctional eye mask and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106580798A (en) * | 2016-12-30 | 2017-04-26 | 广州科盈化妆品有限公司 | All-in-one eye cream and preparation method |
| CN110169946A (en) * | 2019-05-30 | 2019-08-27 | 科索瑞生物科技(天津)有限公司 | Eye essence cream and preparation method thereof |
| CN110742831A (en) * | 2019-10-29 | 2020-02-04 | 浙江英树生物科技有限公司 | Brightening eye brightening and night-out eye mask essence and preparation method thereof |
| CN111419784A (en) * | 2020-05-07 | 2020-07-17 | 深圳市玉莱漫科技发展有限公司 | NMN-containing anti-wrinkle eye cream and preparation method and application thereof |
-
2020
- 2020-09-18 CN CN202010989222.6A patent/CN112206200A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106580798A (en) * | 2016-12-30 | 2017-04-26 | 广州科盈化妆品有限公司 | All-in-one eye cream and preparation method |
| CN110169946A (en) * | 2019-05-30 | 2019-08-27 | 科索瑞生物科技(天津)有限公司 | Eye essence cream and preparation method thereof |
| CN110742831A (en) * | 2019-10-29 | 2020-02-04 | 浙江英树生物科技有限公司 | Brightening eye brightening and night-out eye mask essence and preparation method thereof |
| CN111419784A (en) * | 2020-05-07 | 2020-07-17 | 深圳市玉莱漫科技发展有限公司 | NMN-containing anti-wrinkle eye cream and preparation method and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| 电子凭证-国产非特殊用途化妆品备案信息服务平台: "可贝尔双蛋白水晶眼贴膜", 《FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/NEW_INFO/CHANGE_DZPZ.JSP?PROCESSID=202008130921061U0OR&BA_PARAM=MJAYMC0WOC0XOA==》 * |
| 电子凭证-国产非特殊用途化妆品备案信息服务平台: "可贝尔眼袋平水晶眼贴膜", 《FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=20171122142928PDDGA&NID=20171122142928PDDGA》 * |
| 电子凭证-国产非特殊用途化妆品备案信息服务平台: "姿氧胶原蛋白弹润紧致眼贴膜", 《FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=202007311548430E4I3&NID=202007311548430E4I3》 * |
| 电子凭证-国产非特殊用途化妆品备案信息服务平台: "真琴眼袋型水晶眼膜", 《FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=20190411153857C1NEA&NID=20190411153857C1NEA》 * |
| 电子凭证-国产非特殊用途化妆品备案信息服务平台: "誓妍鎏光多肽眼膜贴", 《FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=202004231026492NN5J&NID=202004231026492NN5J》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112603871A (en) * | 2021-02-05 | 2021-04-06 | 东晟源研究院(广州)有限公司 | Formula and preparation method of wrinkle-reducing eye essence |
| CN113786376A (en) * | 2021-09-26 | 2021-12-14 | 湖北省麦诗特生物科技有限公司 | Eye cream composition with eyeprint removing effect and preparation method thereof |
| CN113876656A (en) * | 2021-10-29 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | Black eye and pouch removing soluble beautifying microneedle patch composition and preparation method thereof |
| CN115006322A (en) * | 2022-06-06 | 2022-09-06 | 广东丸美生物技术股份有限公司 | Formula of instant and long-acting multifunctional eye mask and preparation method thereof |
| CN115006322B (en) * | 2022-06-06 | 2023-09-19 | 广东丸美生物技术股份有限公司 | Formula and preparation method of multifunctional eye mask with instant and long-acting effects |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112206200A (en) | Full-effect crystal eye mask and preparation method thereof | |
| CN105769698B (en) | A kind of cosmetic composition and its application without preservative | |
| CN108113914B (en) | Essence cream without essence and preservative and preparation method thereof | |
| CN109953926B (en) | Skin care product with five-vitamin anti-wrinkle and anti-aging effects and preparation method thereof | |
| CN109674724B (en) | A kind of sleep mask and preparation method thereof containing dendrobium nobile | |
| CN110227038B (en) | Freeze-dried powder with whitening activity and preparation method and application thereof | |
| CN112022751A (en) | Tightening lifting mask | |
| CN111150686A (en) | Primary muscle activation polypeptide-squalane fresh massage eye cream | |
| KR102071627B1 (en) | Peeling gel composition for removing keratin of skin and manufacturing method thereof | |
| CN105560119A (en) | Peony moisturizing lotion and preparation method thereof | |
| CN113712883B (en) | Repairing cream containing dendrobium officinale extract and preparation method of repairing cream | |
| CN114748367A (en) | Moisturizing repair essence and preparation method thereof | |
| CN110559226A (en) | Whitening lotion and preparation method thereof | |
| CN104434642A (en) | Whitening and moisturizing gel for after-sun repairing and preparation method thereof | |
| EP2596787B1 (en) | New use of hesperetin | |
| CN104027280A (en) | Anti-aging traditional Chinese medicine composition and application of anti-aging traditional Chinese medicine composition in cosmetics | |
| CN111084742B (en) | Non-invasive skin care compositions for skin barrier repair | |
| CN109771326B (en) | Composition for whitening and repairing mask | |
| CN111557872A (en) | Skin care product of multi-oligopeptide composition | |
| CN104922008A (en) | Essence capable of removing color spots | |
| CN111728924A (en) | Whitening mask and preparation method thereof | |
| KR20210072966A (en) | Nanocapsule composition for skin moisturizing or skin inflammatory improvement comprsing encapsulated centella and calamine | |
| CN112370404B (en) | Moisturizing and whitening composition, and preparation method and application thereof | |
| CN115040448A (en) | Skin care product with enhanced anti-aging effect and preparation method thereof | |
| CN113876671A (en) | Anti-aging composition containing rape bud extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210112 |